Neil Maitra
Cardiovascular Disease · la Jolla, CANPI 1073142675
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,844, 7.5 times the $246 reported in 2023.
Across 75 payments — averaging $44.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$706
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$421
- Medtronic$373
- Novartis$270
- Boston Scientific$261
- Kestra Medical Technology Services, Inc.$253
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,08292%
- Education$2698%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 4 | $706 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $421 |
| Medtronic | 6 | $373 |
| Novartis | 12 | $270 |
| Boston Scientific | 4 | $261 |
| Kestra Medical Technology Services, Inc. | 7 | $253 |
| Shockwave Medical, Inc | 1 | $156 |
| Bridgebio Pharma, Inc. | 1 | $128 |
| Merck | 1 | $120 |
| Cook Medical LLC | 1 | $108 |
| Kiniksa Pharmaceuticals International, PLC | 5 | $100 |
| Irhythm Technologies, Inc. | 3 | $64 |
| Philips North America LLC | 2 | $58 |
| Cvrx, Inc. | 2 | $42 |
| AstraZeneca | 2 | $39 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Lantheus Medical Imaging, Inc. | 1 | $34 |
| Abiomed | 1 | $33 |
| Pfizer | 1 | $29 |
| Novo Nordisk | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,351 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $40,128 |
| Praluent PenAlirocumab | 11 | $9,153 |
| Metoprolol Succinate | 48 | $649 |
| Atorvastatin Calcium | 20 | $374 |
| Rosuvastatin Calcium | 14 | $262 |
| Furosemide | 13 | $226 |
| ClopidogrelClopidogrel Bisulfate | 18 | $213 |
| Losartan Potassium | 26 | $204 |
| Carvedilol | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $29 | $40,12826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in la Jolla
- Eric Topolla Jolla$2.2M
- Pam Taubla Jolla$1.2M
- Douglas Gibsonla Jolla$727K
- Douglas Triffonla Jolla$176K
- Judith Swainla Jolla$151K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Cathleen Bairey-MerzLos Angeles$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.